Roberta J Weiss

20120177596, Jul 12, 2012

Nov 3, 2011

13/288299

Steven A. Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

ABBOTT BIOTECHNOLOGY LTD. - HAMILTON

A61K 39/395
A61P 1/00
A61P 1/04
A61K 38/20

424 852, 4241581, 4241351

Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

20130004507, Jan 3, 2013

Jun 22, 2012

13/530363

Steven A. Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

Abbott Biotechnology Ltd. - Hamilton

A61K 39/395
A61P 37/06
A61P 31/00
A61P 37/00
A61P 35/00
A61P 29/00

4241581

Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

20030235585, Dec 25, 2003

Jun 5, 2002

10/163657

Steven Fischkoff - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

A61K039/395

424/145100, 424/141100

Methods of treating disorders in which TFN activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF (e.g., K=10M or less), a slow off rate for hTNF dissociation (e.g., K=10secor less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.

20150023982, Jan 22, 2015

Sep 26, 2014

14/498952

Steven A. FISCHKOFF - Short Hills NJ, US
Joachim Kempeni - Neustadt, DE
Roberta Weiss - Wynnewood PA, US

AbbVie Biotechnology Ltd. - Hamilton

C07K 16/24

4241581

Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.